Elizabeth Buck
Fundador en BLACK DIAMOND THERAPEUTICS, INC. .
Fortuna: 455 018 $ al 31/05/2024
Origen de la red de primer grado Elizabeth Buck.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 23 | |
| Public Company | Electrical Products | 5 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Elizabeth Buck a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MEDIABAY INC | Internet Retail | Director/Board Member | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
| GENOCEA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Investor Relations Contact | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Doctorate Degree | |
Bain & Co., Inc.
 Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Imperial College London | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree | |
Morgan Stanley Venture Partners
 Morgan Stanley Venture Partners Investment ManagersFinance Morgan Stanley Venture Partners (MSVP) is a venture capital firm subsidiary of Morgan Stanley Investment Management Merchant Banking, which is ultimately owned by Morgan Stanley (NYSE: MWD) founded in 1986.The firm is headquartered in New York. | Investment Managers | Private Equity Analyst | |
| University of Toronto | College/University | Undergraduate Degree Doctorate Degree | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Chairman Corporate Officer/Principal | |
| All India Institute of Medical Sciences | College/University | Doctorate Degree | |
| Royal College of Art | College/University | Corporate Officer/Principal | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Operating Officer | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
| Kapital Consulting LLC | Founder | ||
| Sarcoma Alliance for Research through Collaboration | Director/Board Member | ||
| AXCA HEALPAR | Biotechnology | Corporate Officer/Principal Director of Finance/CFO Director of Finance/CFO | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| CRISPR THERAPEUTICS AG | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
| University of Pennsylvania Medical Center | College/University | Doctorate Degree | |
| ARCELLX, INC. | Biotechnology | Director/Board Member | |
| STOKE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| Versant Ventures (Switzerland) GmbH | Investment Managers | Private Equity Investor Private Equity Analyst | |
| OYSR POIN | Pharmaceuticals: Major | Chairman | |
| NKARTA, INC. | Biotechnology | Chairman | |
New Enterprise Associates LLC
 New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Investment Managers | Corporate Officer/Principal | |
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Monte Rosa Therapeutics AG
 Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member Corporate Officer/Principal | |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
858 Therapeutics, Inc.
 858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
| NUVATION BIO INC. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Pharmaceuticals: Major | Director/Board Member | |
| FirstLight Bio, Inc. | Director/Board Member | ||
SpyGlass Pharma Inc
 SpyGlass Pharma Inc Miscellaneous Commercial ServicesCommercial Services Spyglass Ophthalmics, Inc. develops products for vision and eye care. The company was founded by Malik Y. Kahook and Glenn Sussman and is headquartered in Mission Viejo, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Launchpad Therapeutics, Inc.
 Launchpad Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Launchpad Therapeutics, Inc. develops novel therapeutics. | Miscellaneous Commercial Services | Director/Board Member President | |
Nexo Therapeutics, Inc.
 Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022. | Pharmaceuticals: Major | Director/Board Member | |
| ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member |
Estadísticas
Internacional
| Estados Unidos | 36 |
| Suiza | 6 |
| Reino Unido | 6 |
| Canadá | 2 |
| India | 2 |
Sectorial
| Health Technology | 30 |
| Consumer Services | 9 |
| Commercial Services | 5 |
| Finance | 5 |
| Retail Trade | 2 |
Operativa
| Director/Board Member | 231 |
| Corporate Officer/Principal | 101 |
| Independent Dir/Board Member | 94 |
| Chairman | 69 |
| Undergraduate Degree | 23 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Richard Berman | 61 |
| Robert Alexander Ingram | 43 |
| Bradley Bolzon | 41 |
| Kapil Dhingra | 39 |
| Ali Behbahani | 35 |
| Wendy Dixon | 25 |
| H. Philip Goodeve | 21 |
| Garry Menzel | 19 |
| Alexander Mayweg | 18 |
| Thilo Schroeder | 18 |
| Rachel Humphrey | 17 |
| Douglas A. Hamilton | 16 |
| Raj Shah | 16 |
| Patrick T. Mooney | 15 |
| Mark Velleca | 14 |
- Bolsa de valores
- Insiders
- Elizabeth Buck
- Conexiones Empresas
